Active Cancer NIHR-supported project Digestion, Kidneys & Other Organs

A Modular, Multi-Part, Multi-Arm, Phase 1/2 Study to Evaluate the Safety and Tolerability of CT7439 Alone and in Combination with Anticancer Treatments in Participants with Solid Malignancies

Funder NIHR (part of DHSC)
Recipient organisation NIHR Biomedical Research Centre at the Royal Marsden and the ICR Source-published name: NIHR Royal Marsden Biomedical Research Centre
NIHR support Recorded as supported by this research centre
Period Jan 2025 — Sept 2026

In plain English

AI plain-English summary

A new cancer drug called CT7439 is being tested in people for the first time, in a study that will give it to up to 100 patients across the UK and USA. This matters because CT7439 targets a specific enzyme that drives abnormal growth in some solid tumour cancers. Laboratory studies suggest the drug may work both on its own and in combination with other anticancer treatments, but it has never been given to humans before. The study will determine the drug’s side effects, the correct dose, how much enters the bloodstream, and how quickly the body clears it. If the drug proves safe and shows signs of shrinking tumours, it could lead to larger trials and eventually a new treatment option for patients with cancers that are hard to treat. The modular design of the trial—starting with CT7439 alone, then adding other drugs—allows researchers to test combinations efficiently. Patients who benefit may continue receiving the drug after the main study ends, and all participants will be followed for up to 18 months to track long-term outcomes.

View original technical description
The purpose of the CT7439_001 study, sponsored by Carrick Therapeutics Ltd., is to determine the side effects and dose to use in future clinical trials of the study drug, CT7439, in patients with cancer. The study will also determine how much of the study drug gets into the bloodstream, how quickly the body removes it and how well the study drug works.CT7439 is a drug which targets an enzyme in the body responsible for the abnormal growth in some cancer cells and is being developed to treat solid tumour cancers. Based on laboratory studies, CT7439 has demonstrated potential if used on its own and also in combination with other anticancer treatments. CT7439 has not been given to people before. This study will assess the study drug as a therapy on its own (module 1), before being combined with other anticancer treatments (module 2). Patients will be in the study for up to 7 months, however the duration will depend on how the participant responds to study drug. All participants will be followed long term for up to 18 months. After completing the main study, participants who derive benefit from CT7439 may be eligible to continue receiving study drug. Up to 100 participants across two countries (UK and USA) will take part in module 1.

Researchers

Adam Sharp (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

A Modular, Multipart, Multiarm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination with Anticancer Treatments in Patients with Advanced Malignancies.
A Modular, Multipart, Multiarm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies
A Modular Phase I/IIa, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination with Anti-cancer Agents in Patients with Solid Tumors
A Modular Phase I/IIa, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination with Anti-cancer Agents in Patients with Solid Tumors.
A Modular Phase I/IIA, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Doses of AZD3553 Monotherapy and in Combination with Anti-cancer Agents in Participants with Solid Tumors

Original classification

Early Phase Drug Development

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.